GlassScriptPhysician profile
Jacqueline Browning
NPI 1083376339
$2,721.41
in general payments reported to CMS, 2019-2025
21 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $1,027 · 2023: $602 · 2024: $619 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.29 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,065.83 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $432.52 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $300.24 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.04 | 2021-2023 | |
| Lundbeck LLC | $156.56 | 2022-2024 | Abilify Maintena, Rexulti |
| Novo Nordisk INC | $126.68 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $76.25 | 2022 | |
| Avanir Pharmaceuticals, INC. | $72.06 | 2021-2022 | |
| Amgen INC. | $53.29 | 2022-2024 | Repatha |
| Vanda Pharmaceuticals INC. | $41.71 | 2021-2022 | |
| Corium, LLC | $32.70 | 2022-2023 | Azstarys |
| Esperion Therapeutics, INC. | $29.09 | 2022 | |
| Alkermes, INC. | $27.09 | 2025 | Vivitrol |
| Medtronic, INC. | $21.24 | 2022 | |
| Indivior INC. | $19.91 | 2025 | Sublocade |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.99 | 2021 | |
| Dexcom, INC. | $13.56 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.37 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.83 | 2022 | |
| Inogen, INC. | $4.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.